Otsuka enters the API business after Astellas asset acquisition

By Ben Hargreaves

- Last updated on GMT

Otsuka Chemical enters the API business

Related tags Astellas Otsuka Chemical Cefixime Antibiotics

Otsuka acquires Astellas’ Cefixime business, which means it will supply the API to overseas licensees and thereby enter the API business.

Otsuka Chemical will acquire the Cefixime business from fellow Japanese firm, Astellas Pharma, which allows the former company to build on its existing antibiotic intermediates business with the addition of antibiotic active pharmaceutical ingredients (APIs).

Cefixime was developed by Astellas and is a third-generation cephalosporin antibiotic that is active against gram-positive and gram-negative bacteria. It is used to treat various conditions, including ear infections, tonsillitis, and pneumonia.

The acquisition sees Otsuka gain the rights to supply the API to overseas licensees, as well as picking up contracts belonging to the licensing business and the trademark.

Moving forward, Otsuka stated that it will strengthen the “manufacturing technology of high-quality API and their marketing and brand power to promote pharmaceutical-related business.”

The divestiture for Astellas fits in with a shift in strategy that has seen the company prioritise its ophthalmology portfolio​, as well as reducing its activity in the area of antibody-drug conjugates​.

Financials of the acqusitions were not revealed.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more